FORTY SEVEN, INC.
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies | Business Wire
New directions for emerging therapies in acute myeloid leukemia: the next chapter | Blood Cancer Journal
PhI/II AZA/VEN/MAG - Slideset Download - | CCO
ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML | Leukemia and Lymphoma Society
Forty Seven (FTSV) On A Roll, Up Over 300% In 2 Months
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma - ScienceDirect
CD47-SIRPα Drug Target Minireview - Drug Hunter
EHA Library - The official digital education library of European Hematology Association (EHA)
Magrolimab - Multiple Myeloma Clinical Trials
Magrolimab combination with azacitidine enhances therapeutic... | Download Scientific Diagram
Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
Magrolimab + Azacitidine vs Venetoclax Acute Myeloid Leukemia
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma | Future Oncology
Brian Skorney on Twitter: "Magrolimab + aza data out. CR rate in 2019 was 50% in high risk MDS. Down to 42% in 2020. Now 33% today. Contrast with 32% CR with
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
Cells | Free Full-Text | Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
